Skip to content
Search

Latest Stories

Denmark study finds how a drop of blood can detect HIV, hepatitis B, hepatitis C

At the European Conference of Clinical Microbiology & Infectious Diseases (ECCMID) this year in Copenhagen, Denmark, data on a test that may detect HIV, hepatitis B, and hepatitis C from a single drop of blood are being presented.

Hepatitis B or C claim the lives of over a million people each year. Every year, 1.5 million individuals contract HIV, and 650,000 people pass away from HIV-related causes.


The World Health Organisation has made the elimination of all three viruses by 2030 one of its global health strategies but new tests are necessary if case numbers are to be reduced.

The most common test for hepatitis B, hepatitis C and HIV involves taking a blood sample from a vein using a needle. While this method works extremely well, there is a potentially large reservoir of the three conditions in places where this method is not suitable.

This could be prisons, drug rehabilitation centres and homeless shelters, where the taking of venous blood samples isn't always suitable or countries in which the shipping and refrigerated storage of blood samples can be challenging.

Alternatives include dried blood spot tests, in which a single spot of blood is tested for nucleic acid from the three viruses.

Stephen Nilsson-Moller and colleagues at the Department of Clinical Microbiology, Copenhagen University Hospital, Denmark validated one such test.

To do the test, the individual's finger is pricked and a few spots of blood collected on filter paper and allowed to dry.

The Hologic Panther System - testing equipment widely found in public health laboratories - then uses a technique called transcription mediated amplification to analyse one of the blood spots for genetic material from the three viruses.

The analysis is designed to be, and is normally, run on liquid samples of plasma or serum - not the dried samples used here.

Twenty samples with known amounts of HIV, hepatitis B and hepatitis C were analysed via the dried blood spot method (60 in total) and the viruses were detected in all of the samples.

The plasma was also diluted to determine the lower limit of detection. This showed that it was possible to detect the viruses at levels that are much lower than are normally found in untreated patients.

Nilsson-Moller says: "We've shown that using existing hospital equipment, it is possible to detect HIV, hepatitis B and hepatitis C from a single drop of blood.

"The dried blood spot test is ideal for places where you don't want to use a needle for safety reasons or where it is less practical. This includes prisons, drug rehabilitation centres and homeless shelters.

"It is also suitable for developing countries or places where you run the risk of a blood sample being ruined before it is transferred to a laboratory that can analyse it.

"Blood samples need to be analysed within six hours when kept at room temperature, while dried blood spots can last for nine months without refrigeration."

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less